Seismic Therapeutic has dosed the first healthy participant cohort in the randomised Phase I trial of bifunctional antibody S-4321 to treat various autoimmune conditions.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,